Holen Sie sich die Stockscreener-App
70.91
3.76%
-2.77
Handel nachbörslich:
70.91
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokineti - GuruFocus
Cytokinetics EVP Andrew Callos sells $1.11m in stock By Investing.com - Investing.com Australia
Insider Sell Alert: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics director Parshall sells $370,400 of CYTK stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP Andrew Callos sells $1.11m in stock - Investing.com
Cytokinetics director Edward Kaye sells $223,171 in shares - Investing.com
Cytokinetics director Parshall sells $370,400 of CYTK stock - Investing.com
Cytokinetics director Edward Kaye sells $223,171 in shares By Investing.com - Investing.com India
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Cytokinetics (CYTK) Launches Myqorzo in Germany for Heart Condition Treatment - GuruFocus
Cytokinetics announces launch of Myqorzo (aficamten) in Germany for symptomatic obstructive hypertrophic cardiomyopathy - marketscreener.com
Cytokinetics launches heart drug Myqorzo in Germany By Investing.com - Investing.com Nigeria
Cytokinetics Announces European Launch of MYQORZO® (aficamten) for Obstructive Hypertrophic Cardiomyopathy in Germany Following U.S. Approval - Quiver Quantitative
Cytokinetics launches Myqorzo® (aficamten) in European Union, with first commercial availability in Germany - marketscreener.com
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany - The Manila Times
New heart drug MYQORZO reaches German patients with obstructive HCM - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Why Cytokinetics Inc. Shares Soared - AOL.com
Cytokinetics, Inc. (CYTK) Stock Analysis: Exploring a 36.40% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
What Makes Cytokinetics' MYQORZO Launch a Game Changer - Kavout
CYTK News | CYTOKINETICS INC (NASDAQ:CYTK) - ChartMill
Biotech Catalysts Put Three Small Caps On Watch - Kalkine Media
Cytokinetics Insider Sold Shares Worth $579,075, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (CYTK) CEO trims stake with 7,500-share stock sale - Stock Titan
Citi Calls Cytokinetics, Incorporated (CYTK) a “Top Pick” Among Small-to-Mid Cap Biotech Stocks - Insider Monkey
CYTOKINETICS (CYTK) director awarded shares and new 4,301-share stock option - Stock Titan
Cytokinetics (CYTK) director granted new shares and long-dated stock options - Stock Titan
Cytokinetics (CYTK) director awarded shares and 4,301 stock options - Stock Titan
CYTOKINETICS (CYTK) director receives share grant and 4,301-share option award - Stock Titan
CYTOKINETICS (CYTK) director granted shares and new stock options in Form 4 filing - Stock Titan
Director at Cytokinetics (NASDAQ: CYTK) awarded shares and options - Stock Titan
Director at Cytokinetics (NASDAQ: CYTK) gets new stock and option grants - Stock Titan
Cytokinetics (CYTK) director awarded new stock and option grants - Stock Titan
Cytokinetics (CYTK) director Nancy Wysenski receives stock and 4,301-share option grant - Stock Titan
Cytokinetics (CYTK) investors approve directors, ESPP share increase and auditor - Stock Titan
Cytokinetics to Participate in June Investor Conferences - GlobeNewswire
Cytokinetics says MYKORZO launch tops expectations as HCM data draws praise - MSN
‘You have to be an optimist in drug discovery’ - Scientific American
A Look At Cytokinetics (CYTK) Valuation After A Strong Multi‑Year Share Price Performance - Yahoo Finance
Cytokinetics, Incorporated (CYTK) Stock Analysis: A 36% Potential Upside In Biotechnology - DirectorsTalk Interviews
Cytokinetics’s SWOT analysis: biotech stock faces profitability test By Investing.com - Investing.com South Africa
Cytokinetics’s SWOT analysis: biotech stock faces profitability test - Investing.com
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise - TradingView
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $264,915, According to a Recent SEC Filing - marketscreener.com
Cytokinetics to Hold Annual Meeting of Stockholders - The Manila Times
Cytokinetics (CYTK) R&D EVP exercises options and sells 3,500 shares - Stock Titan
Cytokinetics CEO to review performance after May 27 stockholder meeting - Stock Titan
CYTK: MYQORZO outperforms launch targets, with robust uptake, expanding access, and strong pipeline progress - TradingView
CYTK Initiated Coverage by Citigroup -- Price Target Set at $99. - GuruFocus
Cytokinetics Inc stock (US2328281044): pipeline updates keep biotech in focus - AD HOC NEWS
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
GABELLI & Co INVESTMENT ADVISERS INC. Sells 23,900 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM - American Heart Association Journals
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 7,500 Shares of Stock - MarketBeat
2.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):